Top 5 Liquid Biopsy Companies

Published: May 2026

Liquid biopsy has emerged as a transformative diagnostic modality in the healthcare analytics industry, as it enables the non-invasive detection of disease-related biomarkers from biological fluids such as blood, urine, and saliva. This technology provides a real-time molecular snapshot of a patient’s health by analyzing ctDNA (circulating tumor DNA), CTCs (circulating tumor cells), exosomes along with various other biomarkers, which are shed into the bloodstream by diseased tissues. The clinical utility of liquid biopsy gained significant prominence due to its ability to overcome the limitations of traditional tissue biopsies, which are often invasive, localized, and difficult to repeat.

To date, close to 230 liquid biopsy solutions have been commercialized, with almost 70 solutions currently under development as potential liquid biopsy solutions. Furthermore, the overall success of liquid biopsy solutions for oncology has piqued the interest of numerous investors, facilitating the global scaling of advanced liquid biopsy platforms.

As the liquid biopsy market expands across diverse diagnostic and monitoring applications, clinical researchers and healthcare providers are actively seeking efficient, scalable platforms for genomic profiling and cancer detection. This increasing demand offers significant opportunities for liquid biopsy companies to enhance their service portfolios and support the global advancement of precision oncology in the coming years.

Roots Analysis has conducted an exhaustive study on Liquid Biopsy Market featuring the current market landscape and future opportunities for companies engaged in healthcare, over the span of next 9 years.

Top Five Leading Liquid Biopsy Companies

1. BioCartis
2. Exact Sciences
3. Lucence
4. nRichDX
5. Qiagen

Top 5 companies to watch Liquid Biopsy Market

Interested in exploring all ~120 players offering liquid biopsy solutions, along with their recent initiatives?

Access Detailed Insights

Discover Below the Details on Top 5 Liquid Biopsy Companies

Let us dive deep into the details of the top liquid biopsy companies. It is essential to note that the selection of top players can differ substantially according to the defined criteria.

1. BioCartis

Company Overview

Biocartis is a life sciences company specializing in next generation sequencing market, for a range of indications including melanoma, colorectal cancer, lung cancer, SARS-CoV-2, and sepsis. The company is actively engaged in the manufacturing of various liquid biopsy products, notably the MDx Idylla platform. This platform is a fully automated real-time PCR system designed to deliver molecular information from any biological sample and can be utilized in diverse settings. It employs customized panels tailored for oncological and infectious disease applications. Presently, Biocartis has successfully deployed approximately 2,000 units of its platform across 75 countries.

List of Type of Solution, Type of Technology, Type of Sample, Type of Circulating Biomarker, Type of Cancer and Solution Purpose

The section provides information on the various solutions being provided by BioCartis, along with details on stage of development, type of solution, type of technology, type of sample, type of circulating biomarker, type of cancer, solution purpose, and application area dedicated to liquid biopsy.

Type of Solution: Devices, Assay Kits
Type of Technology: Polymerase Chain Reaction
Type of Sample: Blood, Plasma, Others
Type of Circulating Biomarker: Cell Free DNA (cfDNA), Circulating Tumor DNA (ctDNA), Unspecified DNA
Type of Cancer: Lung Cancer, Blood Cancer, Gastrointestinal Cancer, Breast Cancer
Solution Purpose: Research Purpose

Recent Developments

In November 2025, Biocartis showcased the growing impact of Idylla™ Platform at the Association for Molecular Pathology (AMP) Annual Meeting, held at Massachusetts. This will help the company to highlight its capabilities in this domain to accelerate growth and enhance patient access to molecular testing.

To know more about the recent initiatives of Biocartis and other liquid biopsy companies, access full report.

2. Exact Sciences

Company Overview

Exact Sciences is a leading American molecular diagnostics company specializing in early cancer detection and prevention through advanced liquid biopsy technologies. The company is recognized for its FDA-approved Cologuard stool-based DNA test introduced for colorectal cancer screening. Its portfolio has expanded to include precision oncology products such as Oncotype DX, which assesses recurrence risk, and OncoExTra, designed for solid tumor profiling to guide therapeutic decisions.

The company is also developing Oncoliquid, intended to support therapy selection in advanced cancer cases, and maintains a strategic partnership with Mayo Clinic focused on multi-cancer biomarker research.

List of Type of Solution, Type of Technology, Type of Sample, Type of Circulating Biomarker, Type of Cancer, Solution Purpose, and Application Area

The section provides information on the various solutions being provided by Exact Sciences, along with details on stage of development, type of solution, type of technology, type of sample, type of circulating biomarker, type of cancer, solution purpose, and application area dedicated to liquid biopsy.

Type of Solution: Assay Kits
Type of Technology: Next Generation Sequencing
Type of Sample: Blood, Others
Type of Circulating Biomarker: Circulating Tumor DNA (ctDNA), Unspecified DNA
Type of Cancer: Liver Cancer, Gastrointestinal Cancer
Solution Purpose: Clinical Purpose
Application Area: Treatment Selection, Patient Monitoring, Early Cancer Detection

Recent Developments

In March 2026, Exact Sciences presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting highlighting new data in molecular residual disease (MRD) testing and multi-cancer early detection (MCED). This will eventually help the company to build tools that give clinicians a clearer view of cancer biology and how disease evolves over time.

To know more about the recent initiatives of Exact Sciences and other liquid biopsy companies, access full report.

Request Sample Pages

3. Lucence

Company Overview

Lucence is a biotechnology company specializing in precision medicine and cancer diagnostics. The company is at the forefront of leveraging advanced genomics and artificial intelligence to develop innovative solutions for cancer detection and treatment. Their expertise lies in liquid biopsy technology, which allows for non-invasive cancer screening and monitoring using a simple blood test. These liquid biopsy solutions not only facilitate early cancer detection but also play a pivotal role in tailoring personalized treatment plans. Lucence's unwavering commitment to research and development ensures that their liquid biopsy technologies continue to evolve, potentially expanding their applications to a wide range of cancer types and stages.

List of Type of Solution, Type of Technology, Type of Sample, Type of Circulating Biomarker, Type of Cancer, Solution Purpose, and Application Area

The section provides information on the various solutions being provided by Lucence, along with details on stage of development, type of solution, type of technology, type of sample, type of circulating biomarker, type of cancer, solution purpose, and application area dedicated to liquid biopsy.

Type of Solution: Assay Kits
Type of Technology: Polymerase Chain Reaction, Next Generation Sequencing
Type of Sample: Blood
Type of Circulating Biomarker: Circulating Tumor DNA (ctDNA), Unspecified DNA, RNA
Type of Cancer: Head and Neck Cancer, Breast Cancer, Reproductive Cancer, Gastrointestinal Cancer, Liver Cancer, Lung Cancer, Blood Cancer
Solution Purpose: Clinical Purpose
Application Area: Treatment Selection, Patient Monitoring, Early Cancer Detection, Others

Recent Developments

In March 2026, Lucence Diagnostics and Partners Pathology entered a collaboration to expand access to cancer diagnostics and personalized medicine in Malaysia. This partnership combines Lucence’s molecular testing with latter company’s histopathology services to provide enhanced cancer detection and treatment selection.

To know more about the recent initiatives of Lucence and other liquid biopsy companies, access full report.

4. nRICH dx

Company Overview

nRICH dx is a pioneering company in liquid biopsy sample preparation, providing a platform that produces substantially higher yields of analytes including cell-free DNA, circulating tumor DNA, cell-free total nucleic acids, and cell-free RNA compared to currently available systems. Their 510(k)-exempt universal sample preparation system addresses a significant challenge in precision medicine, which is the insufficient availability of target material that impacts up to fifty percent of liquid biopsy tests. nRICH dx improves diagnostic accuracy, streamlines workflow efficiency, and ensures reliable molecular testing outcomes while simultaneously reducing costs and minimizing operational complexity.

List of Type of Solution, Type of Technology, Type of Sample, Type of Circulating Biomarker, Type of Cancer and Solution Purpose

The section provides information on the various solutions being provided by nRICH dx, along with details on stage of development, type of solution, type of technology, type of sample, type of circulating biomarker, type of cancer, solution purpose, and application area dedicated to liquid biopsy.

Type of Solution: Devices, Assay Kits
Type of Technology: Others
Type of Sample: Blood, Plasma, Urine, Others
Type of Circulating Biomarker: Cell Free DNA (cfDNA), Circulating Tumor Cells (CTCs), Circulating Tumor Cells (CTCs) and RNA
Solution Purpose: Clinical Purpose, Research Purpose

Recent Developments

In January 2026, nRICH dx and Hamilton entered a collaboration to integrate the Nrich dx Revolution Plus Sample Prep System utilizing latter company’s Microlab STAR platform. This integration delivers automated, high-yield workflows for liquid biopsy sample preparation, including extraction of cfDNA, cfRNA, cfTNA, and CTCs.

To know more about the recent initiatives of nRICH dx and other liquid biopsy companies, access full report.

5. QIAGEN

Company Overview

QIAGEN is a global leader in molecular diagnostics, specializing in advanced liquid biopsy technologies that support non-invasive diagnostics and personalized medicine. The company has developed a range of innovative products and technologies to enable the extraction, purification, and analysis of circulating tumor DNA and other biomarkers from various sample types, including blood and plasma. These solutions facilitate the accurate detection and monitoring of cancer-related indications. Serving over 500,000 customers worldwide, QIAGEN is committed to empowering the research and healthcare communities by upholding the highest standards of quality, innovation, and accessibility, while continuously pursuing advancements to improve life.

List of Type of Solution, Type of Technology, Type of Sample, Type of Circulating Biomarker, Type of Cancer, Solution Purpose, and Application Area

Type of Solution: Assay Kits
Type of Technology: Polymerase Chain Reaction
Type of Sample: Blood, Plasma, Others
Type of Circulating Biomarker: Cell Free DNA (cfDNA), Circulating Tumor Cells (CTCs), RNA, Extracellular Vesicles
Type of Cancer: Breast Cancer, Gastrointestinal Cancer, Reproductive Cancer, Lung Cancer
Solution Purpose: Research Purpose

Recent Developments

In November 2025, Qiagen acquired Parse Biosciences with the aim to integrate scalable, instrument-free single-cell analysis into its sample technology portfolio. This strategic acquisition has enhanced former company’s liquid biopsy capabilities by enabling high-throughput genomic profiling of individual cells to improve cancer detection and the development of personalized precision medicine.

To know more about the recent initiatives of Qiagen and other liquid biopsy companies, access full report.

What About Other Liquid Biopsy Companies Around the World?

The above article features the top five liquid biopsy companies selected from a pool of around 120 companies that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.

Review Market Landscape

Sources: